Beg MS, et al. - In a large medical claims database, researchers investigated the relationship of several medication classes with pancreatic cancer survival. For this investigation, they analyzed histologically confirmed pancreatic adenocarcinoma diagnosed between 2006 and 2009 from the Surveillance, Epidemiology, and End Results-Medicare database with available part D data. This study comprised 13,702 patients. In patients with pancreatic cancer, use of β-blockers, heparin, insulin, and warfarin were correlated with improved survival while metformin, thiazolidinedione, statins, and combination therapies were not.